Merriman Curhan Ford Reiterates 'Buy' Geron Corporation (GERN); Important Stem Cell Visibility
GERN Hot Sheet
Rating Summary:1 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 4 | New: 8
Merriman Curhan Ford reiterates 'Buy' Geron Corporation (Nasdaq: GERN), valuation range $9-10.
Merriman analyst says, "We view Geron as the established leader in establishing therapeutics against telomerase, which plays an important role in cancer cells. The company is targeting telomerase through direct inhibition and through an immunotherapy (vaccine) approach. To this end, the company’s lead product GRN163L is in multiple clinical trials and represents a promising new cancer therapeutic. Geron also is poised to be a key leader in the embryonic stem cell arena. While volatility is still expected from the stem cell platform at Geron, we believe the increased visibility and data flow from the telomerase program should drive the stock going forward."
To see more analyst ratings on GERN Click Here.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
Merriman analyst says, "We view Geron as the established leader in establishing therapeutics against telomerase, which plays an important role in cancer cells. The company is targeting telomerase through direct inhibition and through an immunotherapy (vaccine) approach. To this end, the company’s lead product GRN163L is in multiple clinical trials and represents a promising new cancer therapeutic. Geron also is poised to be a key leader in the embryonic stem cell arena. While volatility is still expected from the stem cell platform at Geron, we believe the increased visibility and data flow from the telomerase program should drive the stock going forward."
To see more analyst ratings on GERN Click Here.
Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes.
You May Also Be Interested In
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Merriman Curhan FordSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
